Jennewein Biotechnologie produces human milk oligosaccharides (HMOs) as ingredients for general food products, dietary supplements and therapeutic nutrition products that are administered to support the treatment of certain diseases or high-risk patients.
Cell culture experiments have shown, for example, that the pathogen Pseudomonas aeruginosa can be inhibited by the HMOs 2’‑Fucosyllactose and 3-Fucosyllactose. Pseudomonas aeruginosa causes pneumonia, which occurs frequently as a side effect of immunodeficiency. Furthermore, P. aeruginosa, Escherichia coli and Staphylococcus aureus together account for most hospital-acquired nosocomial infections. The oral administration of Fucosyllactoses reduces the risk of infection by these organisms, as well as those caused by Campylobacter jejuni and certain Salmonella species.
Human milk oligosaccharides cannot be digested and do not add calories to food, but they retain the organoleptic properties of other sugars, i.e. they are soluble and sweet.
Jennewein Biotechnologie and its local partners are happy to provide more detailed information about our product offering relating to general and therapeutic nutrition.